Breaking News, Financial News

Financial Report: Dendreon

Revenues down 18% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Dendreon

1Q Revenues: $67.6 million (-18%)

1Q Loss: $72.0 million (loss of $103.9 million 1Q12)

Comments: The company added 33 new accounts for PROVENGE in the quarter, bringing total number to 835. Dendreon anticipates reducing cost of goods sold (COGS) to below 50% of net product revenue in 3Q13.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters